Know Cancer

or
forgot password

18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors


N/A
18 Years
N/A
Open (Enrolling)
Both
Brain Cancer, Gliomas

Thank you

Trial Information

18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors


Inclusion Criteria:



- Registered patient at MSKCC.

- Child-bearing age females must be non-pregnant,(documented by a negative pregnancy
test within the last 2 weeks), non-lactating, and must be using adequate
contraception or be surgically sterile.

- Patients with gliomas

- Patients planning to start anti-AKT and/or anti-VEGF directed therapies .

- Patients with measurable disease on MRI or CT neuroimaging.

Exclusion Criteria:

- Patient is incontinent of urine or stool (which would make them unable to tolerate
lying still for 60 minutes).

- Patient cannot tolerate lying still for a 60 minute session in the PET tomograph.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine & comp biodistribution, clearance, & dosimetry of [18F]FACBC & [18F]FLT tissue/organs w/i the field of view of the dynamic PET imag studies prior-to & during anti-AKT &/or anti-VEGF directed therapies alone or in combin with radia for glioma.

Outcome Time Frame:

2 years

Safety Issue:

Yes

Principal Investigator

Ronald Blasberg, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

08-142

NCT ID:

NCT00832598

Start Date:

January 2009

Completion Date:

January 2013

Related Keywords:

  • Brain Cancer
  • Gliomas
  • 18F-FACBC
  • PET scan imaging
  • 08-142
  • Brain Neoplasms
  • Glioma
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021